Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis.

Cancer cells must adapt their metabolism to meet the energetic and biosynthetic demands that accompany rapid growth of the primary tumor and colonization of distinct metastatic sites. Different stages of the metastatic cascade can also present distinct metabolic challenges to disseminating cancer cells. However, little is known regarding how changes in cellular metabolism, both within the cancer cell and the metastatic microenvironment, alter the ability of tumor cells to colonize and grow in distinct secondary sites. This review examines the concept of metabolic heterogeneity within the primary tumor, and how cancer cells are metabolically coupled with other cancer cells that comprise the tumor and cells within the tumor stroma. We examine how metabolic strategies, which are engaged by cancer cells in the primary site, change during the metastatic process. Finally, we discuss the metabolic adaptations that occur as cancer cells colonize foreign metastatic microenvironments and how cancer cells influence the metabolism of stromal cells at sites of metastasis. Through a discussion of these topics, it is clear that plasticity in tumor metabolic programs, which allows cancer cells to adapt and grow in hostile microenvironments, is emerging as an important variable that may change clinical approaches to managing metastatic disease. Cancer Res; 76(18); 5201-8. ©2016 AACR.

[1]  V. Catalano,et al.  Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer , 2016, The Pharmacogenomics Journal.

[2]  J. Rutter,et al.  Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies. , 2016, Trends in biochemical sciences.

[3]  S. Horvath,et al.  MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. , 2016, Cell reports.

[4]  C. Benelli,et al.  The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents , 2016, International journal of cancer.

[5]  R. Deberardinis,et al.  TCA Cycle and Mitochondrial Membrane Potential Are Necessary for Diverse Biological Functions. , 2016, Molecular cell.

[6]  Takla Griss,et al.  Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis , 2015, PLoS biology.

[7]  A. Balmain,et al.  Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers , 2015, Nature Medicine.

[8]  R. Weinberg,et al.  Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. , 2015, Trends in cell biology.

[9]  M. Wicha,et al.  Metabolic plasticity of cancer stem cells , 2015, Oncotarget.

[10]  G. J. Yoshida.  Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of experimental & clinical cancer research : CR.

[11]  S. Leung,et al.  PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. , 2015, Cell metabolism.

[12]  J. Reis-Filho,et al.  Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival , 2015, The Journal of pathology.

[13]  J. Mi,et al.  Metabolic reprogramming of the tumour microenvironment , 2015, The FEBS journal.

[14]  R. Deberardinis,et al.  Oxidative stress inhibits distant metastasis by human melanoma cells , 2015, Nature.

[15]  S. Biswas.  Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.

[16]  J. Locasale,et al.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses , 2015, Cell.

[17]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[18]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[19]  Rong-rong Cui,et al.  Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value. , 2015, International journal of clinical and experimental pathology.

[20]  K. Tam,et al.  Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents. , 2015, Drug discovery today.

[21]  G. Michailidis,et al.  EMT-induced metabolite signature identifies poor clinical outcome , 2015, Oncotarget.

[22]  B. White,et al.  Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines. , 2015, Cancer letters.

[23]  R. Blasberg,et al.  Metabolic Plasticity of Metastatic Breast Cancer Cells: Adaptation to Changes in the Microenvironment1 , 2015, Neoplasia.

[24]  D. Neal,et al.  A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy , 2015, The Journal of pathology.

[25]  N. Jeoung.  Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers , 2015, Diabetes & metabolism journal.

[26]  A. Clayton,et al.  Extracellular vesicles as modulators of the cancer microenvironment. , 2015, Seminars in cell & developmental biology.

[27]  L. Cantley,et al.  Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. , 2015, Cancer research.

[28]  Rodrigue Rossignol,et al.  Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. , 2015, The international journal of biochemistry & cell biology.

[29]  S. Tavazoie,et al.  Extracellular Metabolic Energetics Can Promote Cancer Progression , 2015, Cell.

[30]  M. Tan,et al.  The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. , 2015, Cancer letters.

[31]  Weiying Zhou,et al.  Breast cancer-secreted miR-122 reprograms glucose metabolism in pre-metastatic niche to promote metastasis , 2015, Nature Cell Biology.

[32]  R. Deberardinis,et al.  Acetate Is a Bioenergetic Substrate for Human Glioblastoma and Brain Metastases , 2014, Cell.

[33]  T. Bathen,et al.  Metabolic characterization of triple negative breast cancer , 2014, BMC Cancer.

[34]  R. Kalluri,et al.  Corrigendum: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis , 2014, Nature Cell Biology.

[35]  M. Pollak,et al.  Metformin directly acts on mitochondria to alter cellular bioenergetics , 2014, Cancer & metabolism.

[36]  R. Kalluri,et al.  PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis , 2014, Nature Cell Biology.

[37]  J. Pouysségur,et al.  Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. , 2014, Biochemical and biophysical research communications.

[38]  Leah Rider,et al.  Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[39]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[40]  T. Copetti,et al.  A mitochondrial switch promotes tumor metastasis. , 2014, Cell reports.

[41]  M. Pollak.  Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment , 2014, Nature Medicine.

[42]  F. Baltazar,et al.  A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer , 2014, BMC Cancer.

[43]  Andrea Glasauer,et al.  Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis , 2014, eLife.

[44]  F. Sotgia,et al.  Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. , 2014, Seminars in cancer biology.

[45]  D. Sabatini,et al.  Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides , 2014, Nature.

[46]  Tao Zhang,et al.  Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. , 2014, International journal of clinical and experimental pathology.

[47]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[48]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[49]  D. Ye,et al.  Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma , 2013, Nature Communications.

[50]  J. Gray,et al.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.

[51]  M. Loda,et al.  The fat side of prostate cancer. , 2013, Biochimica et biophysica acta.

[52]  Junjeong Choi,et al.  Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype , 2013, Breast Cancer Research.

[53]  M. Pollak.  Potential applications for biguanides in oncology. , 2013, The Journal of clinical investigation.

[54]  B. Van Houten,et al.  Metabolic symbiosis in cancer: Refocusing the Warburg lens , 2013, Molecular carcinogenesis.

[55]  T. Yagi,et al.  Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. , 2013, The Journal of clinical investigation.

[56]  M. Notarnicola,et al.  A significant role of lipogenic enzymes in colorectal cancer. , 2012, Anticancer research.

[57]  Charles R. Evans,et al.  The Sedoheptulose Kinase CARKL Directs Macrophage Polarization through Control of Glucose Metabolism , 2012, Cell metabolism.

[58]  Ming Tan,et al.  Glucose Oxidation Modulates Anoikis and Tumor Metastasis , 2012, Molecular and Cellular Biology.

[59]  F. Sotgia,et al.  Using the “reverse Warburg effect” to identify high-risk breast cancer patients , 2012, Cell cycle.

[60]  T. Fan,et al.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.

[61]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[62]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[63]  D. Thamm,et al.  Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo , 2011, Clinical & Experimental Metastasis.

[64]  J. Chi,et al.  Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia , 2011, PLoS genetics.

[65]  R. Rossignol,et al.  Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? , 2011, Biochimica et biophysica acta.

[66]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[67]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[68]  D. Calvisi,et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.

[69]  G. Brooks,et al.  Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. , 2011, Physiological genomics.

[70]  N. Denko,et al.  Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm? , 2011, International journal of cancer.

[71]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[72]  A. Alavi,et al.  Degree of Tumor FDG Uptake Correlates with Proliferation Index in Triple Negative Breast Cancer , 2010, Molecular Imaging and Biology.

[73]  A. Tsirigos,et al.  Ketones and lactate “fuel” tumor growth and metastasis , 2010, Cell cycle.

[74]  I. Ben-Sahra,et al.  The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells , 2010, Autophagy.

[75]  Bao-en Wang,et al.  Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas. , 2010, Hepatobiliary & pancreatic diseases international : HBPD INT.

[76]  Xin Lu,et al.  Metabolomic Changes Accompanying Transformation and Acquisition of Metastatic Potential in a Syngeneic Mouse Mammary Tumor Model* , 2010, The Journal of Biological Chemistry.

[77]  P. Fortina,et al.  The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.

[78]  C. Hellerbrand,et al.  GLUT1 as a therapeutic target in hepatocellular carcinoma , 2009, Expert opinion on therapeutic targets.

[79]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[80]  Julien Verrax,et al.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.

[81]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[82]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[83]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[84]  S. Kridel,et al.  1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer , 2008, Journal of Nuclear Medicine.

[85]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[86]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[87]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[88]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[89]  S. Fais,et al.  Tumor acidity, chemoresistance and proton pump inhibitors. , 2005, Future oncology.

[90]  A. Giatromanolaki,et al.  Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress , 2005, Journal of Clinical Pathology.

[91]  R. Franklin,et al.  Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. , 2005, Mitochondrion.

[92]  M. Pollak,et al.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells , 2005, Breast Cancer Research.

[93]  P. Leedman,et al.  Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. , 2002, The Biochemical journal.

[94]  D. Burstein,et al.  GLUT1 glucose transporter expression in colorectal carcinoma , 1998, Cancer.

[95]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[96]  Robert Schmieder,et al.  Organ-Specific Cancer Metabolism and Its Potential for Therapy. , 2016, Handbook of experimental pharmacology.

[97]  S. Weinberg,et al.  Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.

[98]  Huafeng Zhang,et al.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression , 2015, Cellular and Molecular Life Sciences.

[99]  U. Tateishi,et al.  The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level , 2011, Annals of nuclear medicine.

[100]  M. V. Vander Heiden.  Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.

[101]  I. Ben-Sahra,et al.  The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. , 2010, Autophagy.